Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant chemotherapy plus endocrine therapy vs endocrine therapy in women ≥70 with ER-positive HER2-negative breast cancer according to Genomic Grade
2011-004744-22Phase 3Active
- Sponsor
- Unicancer
- Start
- Feb 2013
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of doxorubicin, docetaxel and cyclophosphamide in breast cancer (2 arms), sponsored by Unicancer. Primary endpoint: Overall survival at 4 years. Started Feb 2013; status: active.
02
Drugs
doxorubicindocetaxelcyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2011-004744-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004744-22.